These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21810649)

  • 1. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
    Tariot PN; Schneider LS; Cummings J; Thomas RG; Raman R; Jakimovich LJ; Loy R; Bartocci B; Fleisher A; Ismail MS; Porsteinsson A; Weiner M; Jack CR; Thal L; Aisen PS;
    Arch Gen Psychiatry; 2011 Aug; 68(8):853-61. PubMed ID: 21810649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproate preparations for agitation in dementia.
    Lonergan E; Luxenberg J
    Cochrane Database Syst Rev; 2009 Jul; (3):CD003945. PubMed ID: 19588348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.
    Tariot PN; Raman R; Jakimovich L; Schneider L; Porsteinsson A; Thomas R; Mintzer J; Brenner R; Schafer K; Thal L; ;
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):942-9. PubMed ID: 16286437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid for agitation in dementia.
    Lonergan ET; Cameron M; Luxenberg J
    Cochrane Database Syst Rev; 2004; (2):CD003945. PubMed ID: 15106227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.
    Profenno LA; Jakimovich L; Holt CJ; Porsteinsson A; Tariot PN
    Curr Alzheimer Res; 2005 Dec; 2(5):553-8. PubMed ID: 16375658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
    Herrmann N; Lanctôt KL; Rothenburg LS; Eryavec G
    Dement Geriatr Cogn Disord; 2007; 23(2):116-9. PubMed ID: 17148938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.
    Gobbi G; Gaudreau PO; Leblanc N
    J Clin Psychopharmacol; 2006 Oct; 26(5):467-73. PubMed ID: 16974186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
    N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial.
    Porsteinsson AP; Tariot PN; Jakimovich LJ; Kowalski N; Holt C; Erb R; Cox C
    Am J Geriatr Psychiatry; 2003; 11(4):434-40. PubMed ID: 12837672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
    Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
    Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
    Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.
    Quinn JF; Raman R; Thomas RG; Yurko-Mauro K; Nelson EB; Van Dyck C; Galvin JE; Emond J; Jack CR; Weiner M; Shinto L; Aisen PS
    JAMA; 2010 Nov; 304(17):1903-11. PubMed ID: 21045096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic divalproex sodium use and brain atrophy in Alzheimer disease.
    Fleisher AS; Truran D; Mai JT; Langbaum JB; Aisen PS; Cummings JL; Jack CR; Weiner MW; Thomas RG; Schneider LS; Tariot PN;
    Neurology; 2011 Sep; 77(13):1263-71. PubMed ID: 21917762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.
    Lopez OL; Wisniewski SR; Becker JT; Boller F; DeKosky ST
    Arch Neurol; 1999 Oct; 56(10):1266-72. PubMed ID: 10520944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R; Cummings J; Raman R; Thal L;
    Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.